What exactly did the FTC allege against Amare Global?

On June 2, 2026, the Federal Trade Commission announced an action against dietary-supplement company Amare Global Holdings Inc. and three of its principals, alleging that they made false, misleading and unsubstantiated claims about the health benefits of supplements marketed for both children and adults, and that they made deceptive earnings claims about the income brand partners could make selling the products. These are allegations the FTC is pursuing, not final findings, and they should be understood as such. On the health-claim side, the FTC alleges that Amare marketed products including Kids Happy Juice, Kids Mood+ and the Happy Juice Product Pack with claims that they could improve or treat mental-health conditions — specifically depression, anxiety and ADHD in children and adults — and that brand partners represented the products as 'scientifically backed' or 'clinically proven' and able to treat or mitigate depression, including by reducing the risk of suicide in children. The FTC's position is that these are objective health claims that require competent and reliable scientific evidence, and that the defendants lacked such evidence. On the earnings side, the FTC alleges Amare made deceptive representations about the money brand partners could earn, claiming that anyone could join and earn specific stated amounts, or supplement or replace their income, even without multi-level-marketing sales experience or a large social-media following. The FTC also noted that two of the named individuals — identified in reporting as a former chief science officer and a founding brand partner — were already subject to prior FTC orders prohibiting false and unsubstantiated claims, and it pursued a contempt motion on that basis, which signals that the conduct is alleged to be a repeat of previously prohibited behaviour. For advertisers, the significance is that the case is built on standing principles: the health-claim substantiation requirement, the prohibition on deceptive earnings claims, and the responsibility of a company for claims made on its behalf. None of these is new, which is exactly why the case functions as a general warning rather than an industry-specific anomaly. For the sector framework see the healthcare social-media compliance guide , and for the endorsement rules the FTC endorsement and reviews guide . The organizing principle is that the FTC alleges unsubstantiated mental-health claims for children and adults and deceptive income claims, built on standing rules every social-selling brand must follow.

What is the substantiation standard for health claims in advertising?

The substantiation standard for health claims in advertising is that any objective claim about what a product does must be supported by competent and reliable scientific evidence at the time the claim is made, and for claims that a product treats, cures, mitigates or prevents a disease, that evidence must be rigorous, well-controlled human clinical evidence — the same high bar that applies to health claims generally, elevated further when the claim touches disease. This standard is what the FTC alleges Amare failed to meet, and understanding it is the key takeaway for any advertiser making product claims. 'Competent and reliable scientific evidence' is a defined concept in FTC practice: it means tests, analyses, research or studies conducted and evaluated in an objective manner by qualified people, using procedures generally accepted in the relevant field to yield accurate and reliable results. It is not testimonials, not a single small or poorly designed study, and not a mechanism-of-action argument untested in humans. The level of evidence scales with the claim. A general wellness statement ('supports a balanced mood') requires reasonable substantiation and must avoid implying disease treatment. A specific structure/function claim, especially one with numbers, requires solid scientific support. A disease-treatment claim ('treats depression', 'reduces anxiety') requires clinical-grade evidence and, critically, may also reclassify the product as an unapproved drug, because claiming to treat a disease is the hallmark of a drug claim rather than a permissible supplement structure/function claim. Establishment claims — phrasing such as 'clinically proven' or 'scientifically backed' — raise the bar rather than lower it, because they represent to consumers that specific proof exists; the advertiser must actually possess that proof, and vague or aspirational use of these phrases is a common enforcement trigger. The practical compliance approach is to inventory every objective claim in advertising and on labels, match each to the evidence that actually exists, downgrade or delete any claim the evidence does not support, and eliminate disease language entirely for non-drug products. Where a claim is genuinely supported, describe the support accurately rather than inflating it. This discipline protects against exactly the exposure the Amare case illustrates. Screen claim language before publication with the Keyword Risk Checker , and for the medicines-advertising overlay see the healthcare and medicines advertising guide . The organizing principle is that health claims require competent and reliable scientific evidence, with disease-treatment claims demanding clinical-grade proof, so advertisers should make only the claims their evidence actually supports.

Why are health claims about children treated so much more seriously?

Health claims directed at children are treated far more seriously than other claims because they combine the most demanding evidentiary standard with the greatest potential for real-world harm, and the Amare case — where the FTC alleges claims that products could treat depression, anxiety and ADHD in children and even reduce the risk of suicide in children — sits at the extreme end of this sensitivity. Three factors compound to make child-directed health claims uniquely high-risk. The first is the vulnerability of the audience and the decision. Claims aimed at parents about their children's health conditions target a highly motivated, emotionally charged decision, and regulators scrutinise advertising that exploits that vulnerability especially closely. A parent worried about a child's anxiety or attention is not a dispassionate consumer, and a claim offering hope for a serious condition can override normal skepticism. The second is the seriousness of the conditions. Depression, anxiety, ADHD and suicide risk are diagnosable mental-health conditions, so any claim to affect them is a disease-treatment claim of the most demanding kind, requiring clinical-grade evidence that a dietary supplement almost never has. Claiming a supplement reduces suicide risk in children is not a wellness statement; it is a grave medical claim. The third, and most important, is the nature of the harm. The damage from a false child-health claim is not merely financial. If a family, believing a supplement will address a child's mental-health condition, delays or forgoes effective clinical care, the consequence can be serious and even irreversible harm to the child. This potential for physical harm, layered on top of the financial deception, is what elevates the regulatory response. For advertisers, the practical conclusion is unambiguous: any claim that a non-drug product treats, mitigates or prevents a child's mental-health condition should never be made, because the legal, reputational and human downside so overwhelmingly exceeds any marketing benefit that there is no defensible case for it. Brands whose products touch children should hold all child-directed claims to the strictest interpretation, avoid disease language entirely, and treat mental-health claims as off-limits absent drug approval. The sensitivity also connects to children's privacy and advertising restrictions more broadly. For that context see the COPPA amendments guide and the healthcare compliance guide . The organizing principle is that child-directed mental-health claims combine the highest evidentiary bar with the risk of real harm, so advertisers should never claim a non-drug product treats a child's mental-health condition.

What are the rules for income and earnings claims in social selling and MLM?

Income and earnings claims in social selling, multi-level marketing and affiliate structures must be truthful, substantiated and representative of what participants typically achieve — not best-case figures presented as normal, and not guarantees that 'anyone can earn' a specific amount regardless of effort, skill or market — and the FTC's allegation that Amare told brand partners they could earn stated amounts irrespective of experience or audience illustrates precisely the pattern that draws enforcement. Deceptive-earnings claims have been a sustained FTC priority, and the rules are well established. First, income representations must be truthful and reflect typical results. If most participants earn little or nothing, presenting an atypical high earner as representative is deceptive, even if that person's earnings are real. When atypical results are shown, the typical outcome must be disclosed clearly. Second, unfounded guarantees are prohibited. Claims that anyone can join and earn a specific figure — a set amount per month, enough to replace a salary — without regard to the effort, skill, time and market conditions actually required, are the classic deceptive pattern, because they promise an outcome the structure cannot reliably deliver. Third, objective income claims require substantiation, and material limitations must be disclosed rather than buried, so a brand claiming participants earn a certain amount must be able to support it with real data on actual participant outcomes. Social selling amplifies this exposure in a specific way: brand partners routinely post income screenshots, lifestyle imagery, and recruitment pitches that imply easy money, and this content reaches audiences at scale. A brand that provides such representations, encourages them, supplies templates for them, or simply tolerates them while partners post is exposed, because the brand is responsible for the earnings claims made on its behalf. The compliance approach mirrors the health-claim approach: give partners accurate, substantiated typical-results information; prohibit specific-amount guarantees and 'anyone can earn' framing; require that material limitations be disclosed; and monitor partner content, with a process to correct or remove deceptive income posts. Because income claims and health claims often appear together in the same social-selling content, they should be governed by the same partner-compliance program. For how affiliate and partner conduct becomes brand liability, see the affiliate and partner-liability guide , and screen recruitment copy with the Keyword Risk Checker . The organizing principle is that earnings claims must be truthful, typical and substantiated, so brands must supply accurate income information, ban guarantees, and monitor partner posts.

How is a brand liable for what its distributors, affiliates or creators post?

A brand is liable for the claims that its distributors, affiliates and creators make on its behalf because a settled principle of advertising law holds a company responsible for the representations made to promote its products, regardless of who physically posts them — which means brand-partner content is the brand's own legal exposure, not a separate problem confined to the individual, and the Amare case, where the claims at issue flowed largely through brand partners on social media, turns on exactly this principle. The rationale is that a company should not be able to escape responsibility for deceptive marketing by outsourcing the actual speech to a network of promoters. If a brand recruits, incentivises and equips people to sell its products, and those people make unsubstantiated health claims or deceptive income claims, the brand benefits from those claims and is accountable for them. This liability attaches across several kinds of partner conduct. When partners make health claims about the products, the brand is exposed for unsubstantiated claims made on its behalf, so a partner asserting that a supplement treats a disease creates brand liability even if the brand's own official materials are careful. When partners post income or lifestyle content implying easy earnings, the brand is exposed for deceptive earnings representations. And when partners fail to disclose their material connection to the brand — that they are paid or incentivised — the brand can be liable for that failure to disclose under endorsement rules. The consequence is that passivity is not a defence. A brand cannot rely on the fact that it did not personally write the offending post; its failure to control partner claims is itself the exposure. The control measures that follow are concrete: provide partners with an explicit approved-claims list and a prohibited-claims list that bars disease and child-mental-health claims; supply accurate typical-results income information and ban guarantees; require clear disclosure of the material connection in contracts and briefs; and — critically — actively monitor partner social content, with a documented process to correct or remove violations promptly. The monitoring element is what distinguishes a genuine compliance program from a paper one, because regulators look at what the brand actually did to prevent and address violations. The Amare case adds a further note: where individuals are already under prior FTC orders, repeat conduct escalates to contempt, so a history of violations sharply raises the stakes. Verify partner disclosures with the Disclosure Checker , and for the fuller partner-liability framework see the affiliate and partner-liability guide . The organizing principle is that a brand is responsible for claims made on its behalf, so it must govern and monitor partner content rather than treat it as someone else's problem.

What should health and social-selling brands do now to reduce risk?

Health and social-selling brands should respond to the Amare case by tightening three things at once — the substantiation of every product claim, the control of income representations, and the governance of what brand partners post — because the case is a concentrated demonstration that these three standing obligations, not any new rule, are where enforcement lands. Treating it as a checklist of existing duties to verify, rather than a novel development to study, is the right posture. On product claims, the priority is a claims audit. Inventory every objective health claim in advertising, on labels, and in partner materials; match each to the competent and reliable scientific evidence that actually exists; downgrade or delete anything unsupported; and eliminate disease-treatment language ('treats', 'cures', 'mitigates', 'prevents') for any non-drug product. Give special, absolute attention to anything touching children's mental health: claims that a supplement treats or reduces a child's depression, anxiety, ADHD or suicide risk should be removed entirely, because they combine the highest evidentiary bar with the risk of real harm. Verify that establishment phrasing such as 'clinically proven' matches the underlying proof. On income, replace any guarantee or 'anyone can earn' framing with accurate, substantiated typical-results information, disclose material limitations, and prohibit partners from posting specific-amount income promises. On governance, build a real partner-compliance program: an approved-claims and prohibited-claims list, mandatory disclosure of material connections in contracts, training so partners understand the rules, and — most importantly — active monitoring of partner social content with a documented process to correct or remove violations quickly. This monitoring is what regulators look to when assessing whether a brand took reasonable steps. Operationally, integrate pre-publication review into the workflow so claims are checked before they go live rather than after a complaint, and keep records of the substantiation relied on for each claim, so the basis is available if questioned. Because standards and enforcement priorities evolve, confirm current FTC health-claim and endorsement guidance against official sources rather than relying on past practice. Pre-check campaigns and partner materials with the AI Compliance Audit , screen claim and recruitment language with the Keyword Risk Checker , and for the sector framework see the healthcare social-media compliance guide . The organizing principle is that brands reduce risk by substantiating every claim, controlling income representations, and actively governing partner content — the three standing duties the case puts on display.

FTC v. Amare 2026: Supplement Mental-Health Ad Claims

Quick Answer

On June 2, 2026, the US Federal Trade Commission announced an action against dietary-supplement seller Amare Global Holdings and three principals, alleging they made false, misleading and unsubstantiated claims that products including Kids Happy Juice, Kids Mood+ and the Happy Juice Product Pack could treat or mitigate depression, anxiety and ADHD in children and adults — including, the FTC alleges, that products could reduce the risk of suicide in children — and that the company made deceptive earnings claims to brand partners about the income they could make selling the products. The FTC alleges the claims were not supported by adequate scientific evidence, and it noted that two of the individuals were already subject to prior FTC orders prohibiting false and unsubstantiated claims, which it addressed through a contempt motion. For advertisers and brands, the case is a concentrated lesson in three standing rules rather than a new law: health claims — especially disease-treatment claims and any claim about children — require competent and reliable scientific evidence before they are made; earnings claims in multi-level and affiliate structures must be truthful and substantiated; and a brand is responsible for the claims its distributors, affiliates and creators make on its behalf across social media, so brand-partner content is the company's exposure. The practical response is to substantiate every objective claim before publication, prohibit disease and child-mental-health claims that lack evidence, control income representations, and monitor what brand partners post. Screen product and partner claims with the Keyword Risk Checker, check partner disclosures with the Disclosure Checker, and pre-check campaigns with the AI Compliance Audit.

What the FTC Alleged and Why It Matters

On June 2, 2026, the Federal Trade Commission announced an enforcement action against dietary-supplement company Amare Global Holdings Inc. and three of its principals, alleging that they made false, misleading and unsubstantiated claims about the health benefits of supplements marketed for children and adults. The products named include Kids Happy Juice, Kids Mood+ and the Happy Juice Product Pack, and the FTC alleges the defendants claimed these could improve or treat mental-health conditions including depression, anxiety and ADHD. These are allegations the FTC is pursuing; they have not been finally adjudicated, and this guide treats them as such.

The action matters to advertisers well beyond the supplement industry because it is built entirely on standing legal principles rather than any new rule. The FTC's case rests on the requirement that objective health claims be supported by competent and reliable scientific evidence, on the prohibition of deceptive earnings claims, and on the principle that a company is responsible for what its brand partners say on its behalf. Every social-selling, affiliate and creator-driven brand faces the same three rules, which is why the case reads as a warning rather than a niche supplement story.

"Companies cannot make health claims about their products without competent and reliable scientific evidence to back them up, and they certainly cannot promise that their products will treat serious conditions in children.
— Federal Trade Commission, on supplement health-claim enforcement"

This guide separates the health-claim substantiation issue, the heightened sensitivity of claims about children, the deceptive-earnings dimension, and the brand-partner liability lesson, and translates each into a compliance practice. For the sector framework see the healthcare social-media compliance guide, and for the endorsement rules the FTC endorsement and reviews guide.

Health Claims and the Substantiation Standard

The core of the case is substantiation. Under FTC standards, any objective claim about what a product does — and especially any claim that it treats, cures, mitigates or prevents a health condition — must be supported by competent and reliable scientific evidence at the time the claim is made. The FTC alleges Amare lacked that support for its mental-health claims.

The Claim-Risk Hierarchy

Claim type	Evidence required	Risk level
Disease treatment or cure ("treats depression")	Rigorous, well-controlled human clinical evidence	Highest — also raises drug-classification issues
Specific structure/function with numbers	Competent and reliable scientific evidence	High
General wellness ("supports a balanced mood")	Reasonable substantiation; avoid disease implication	Moderate
"Clinically proven" / "scientifically backed"	Must match the actual evidence; establishment claims held to a high bar	High — the phrasing itself raises the standard

Two points from the case generalise. First, describing a supplement as able to treat a diagnosable condition such as depression, anxiety or ADHD crosses from a structure/function claim into a disease-treatment claim, which demands clinical-grade evidence and can also imply the product is functioning as an unapproved drug. Second, establishment phrasing — "clinically proven", "scientifically backed" — raises rather than lowers the bar, because it represents that specific proof exists and must be matched by that proof. The safe practice is to make only claims the evidence actually supports, and to avoid disease language entirely unless the product is a properly approved treatment. Screen claim language before publication with the Keyword Risk Checker, and for the medicines-advertising overlay see the healthcare and medicines advertising guide.

Claims About Children and Mental Health

The dimension that most sharply distinguishes this case is that several products were marketed for children, and the alleged claims reached children's mental health — including, the FTC alleges, that products could reduce the risk of suicide in children. Claims of this kind occupy the most sensitive corner of advertising law, combining the highest evidentiary bar with the greatest potential for harm.

Why Child-Directed Health Claims Carry Extreme Risk

Vulnerable audience: claims aimed at parents about children's health conditions target a highly motivated, vulnerable decision, which regulators scrutinise closely.
Serious conditions: depression, anxiety, ADHD and suicide risk are serious diagnosable conditions, so claims to affect them are disease-treatment claims of the most demanding kind.
Delayed real treatment: the harm is not only financial — a claim that a supplement addresses a child's mental-health condition can lead a family to delay effective care.

For any brand whose products touch children, the lesson is to hold child-directed claims to the strictest interpretation and to avoid entirely any claim that a non-drug product treats or mitigates a child's mental-health condition. This is an area where the reputational and legal downside so far outweighs any marketing benefit that the only defensible position is to not make such claims. The heightened sensitivity also intersects with children's privacy and advertising rules more broadly. For that context see the COPPA amendments guide and the healthcare compliance guide.

Deceptive Earnings Claims in Social Selling

Alongside the health claims, the FTC alleges Amare made deceptive earnings claims about the money brand partners could make selling its products — for example that anyone could join and earn stated amounts such as a set monthly figure, or supplement or replace their income, regardless of experience or audience. This is a distinct violation that applies to any multi-level, affiliate or referral structure, independent of the health-claim issue.

The Earnings-Claim Rules

Truthful and typical: income representations must be truthful and reflect what participants typically achieve, not a best-case or aspirational figure presented as normal.
No unfounded guarantees: claims that "anyone can earn" a specific amount, without regard to effort, skill or market, are the classic deceptive-earnings pattern.
Substantiation and disclosure: objective income claims need substantiation, and material limitations must be disclosed rather than hidden.

Deceptive-earnings enforcement has been a sustained FTC priority, and social selling amplifies the exposure because brand partners frequently post income screenshots, lifestyle content and recruitment pitches that imply easy earnings. A brand that supplies or encourages such representations, or looks the other way while partners make them, carries the risk. Controlling income messaging — providing accurate typical-results information, prohibiting unfounded guarantees, and monitoring partner posts — is as important as controlling product claims. For how affiliate and partner conduct becomes brand liability, see the affiliate and partner-liability guide.

Brand-Partner and Distributor Liability

The through-line of the case is that the claims at issue were made not only by the company but through its brand partners — the distributors and promoters who sell and market the products, largely on social media. The FTC's action reflects a settled principle that a company is responsible for the claims made on its behalf, which means brand-partner content is the brand's own exposure, not a separate problem belonging to the individual poster.

Where Brand Liability Attaches

Partner conduct	Brand exposure	Control measure
Health claims in partner posts	Brand liable for unsubstantiated claims made on its behalf	Approved-claims list; prohibit disease claims; monitor
Income/lifestyle content	Brand liable for deceptive earnings representations	Accurate typical-results guidance; ban guarantees
Undisclosed material connection	Brand liable for endorsers' failure to disclose	Mandatory disclosure in contracts; verify posts

The practical implication is that a brand using distributors, affiliates or creators must actively govern what they say: provide a clear list of permitted and prohibited claims, prohibit disease and child-mental-health claims outright, supply accurate income information and ban unfounded guarantees, require clear disclosure of the material connection, and monitor partner content with a process to correct or remove violations. Passivity is not a defence — the case underscores that the brand's failure to control partner claims is itself the exposure. Because two individuals were reportedly already under prior FTC orders, the case also shows that repeat conduct escalates. Verify partner disclosures with the Disclosure Checker, and track enforcement developments on the Policy Change Tracker.

Health and Social-Selling Compliance Checklist

[ ] Substantiated every objective health claim with competent and reliable scientific evidence before publication
[ ] Removed all disease-treatment claims for non-drug products (treat, cure, mitigate, prevent)
[ ] Eliminated any claim that a product treats or mitigates a child's mental-health condition
[ ] Verified that "clinically proven" and "scientifically backed" phrasing matches actual evidence
[ ] Provided brand partners with an approved-claims list and prohibited-claims list
[ ] Replaced income guarantees with accurate typical-results information
[ ] Required clear disclosure of material connections in partner contracts
[ ] Implemented monitoring of brand-partner social content with a correction process
[ ] Confirmed no prior FTC orders bind the company or its principals
[ ] Confirmed current FTC health-claim and endorsement standards against official sources

Don't miss the next policy change.

Create a free account — track every policy change across 8 platforms, get instant alerts, and access every free compliance tool. Or try our Meta Rejection Predictor first.

Create Free Account

Report Keywords — Run AI Compliance Audit

#FTC#Health Claims#Dietary Supplements#Endorsements#MLM#Kids & Teens#Ad Compliance#Substantiation#Social Selling#Advertisers#2026 Policy#Compliance Guide 2026

Share This Report

Tweet Share

Platforms

Industries

Knowledge

Blog

FTC v. Amare Global in 2026: Supplement Mental-Health Claims, Children and the Brand-Partner Liability Warning

What the FTC Alleged and Why It Matters

Health Claims and the Substantiation Standard

The Claim-Risk Hierarchy

Claims About Children and Mental Health

Why Child-Directed Health Claims Carry Extreme Risk

Deceptive Earnings Claims in Social Selling

The Earnings-Claim Rules

Brand-Partner and Distributor Liability

Where Brand Liability Attaches

Health and Social-Selling Compliance Checklist

Don't miss the next policy change.

Report Keywords — Run AI Compliance Audit

Share This Report

Related Posts

Hair-Loss Ads 2026: Where Each Platform Draws the Line

Telehealth Ads Cross-Platform 2026: State Licensure Rules

Healthcare & Supplements Advertising Compliance 2026: Platform Rules, Claim Limits, and Enforcement Defense

Related Resources

All Tools

Platform Guides

Knowledge Hub

Policy Tracker